GR3036125T3 - Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines. - Google Patents

Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines.

Info

Publication number
GR3036125T3
GR3036125T3 GR20010400978T GR20010400978T GR3036125T3 GR 3036125 T3 GR3036125 T3 GR 3036125T3 GR 20010400978 T GR20010400978 T GR 20010400978T GR 20010400978 T GR20010400978 T GR 20010400978T GR 3036125 T3 GR3036125 T3 GR 3036125T3
Authority
GR
Greece
Prior art keywords
hbeag
immunoreactivity
immunoassays
vaccines
hepatitis
Prior art date
Application number
GR20010400978T
Other languages
English (en)
Inventor
Michael Noah
Michael Broeker
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of GR3036125T3 publication Critical patent/GR3036125T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/94—Saccharomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GR20010400978T 1991-03-09 2001-06-27 Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines. GR3036125T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4107612A DE4107612A1 (de) 1991-03-09 1991-03-09 Rekombinante proteine mit der immunreaktivitaet des hepatitis b virus e antigens (hbeag), verfahren zu ihrer herstellung und ihre verwendung in immunoassays und impfstoffen

Publications (1)

Publication Number Publication Date
GR3036125T3 true GR3036125T3 (en) 2001-09-28

Family

ID=6426883

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400978T GR3036125T3 (en) 1991-03-09 2001-06-27 Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines.

Country Status (10)

Country Link
US (1) US6277631B1 (el)
EP (1) EP0503252B1 (el)
JP (1) JP3329848B2 (el)
AU (1) AU664982B2 (el)
CA (1) CA2062410A1 (el)
DE (2) DE4107612A1 (el)
DK (1) DK0503252T3 (el)
ES (1) ES2155436T3 (el)
GR (1) GR3036125T3 (el)
PT (1) PT503252E (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323331B2 (en) 2000-08-11 2008-01-29 Advanced Life Science Institute, Inc. Method for detecting or assaying HBV

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK171727B1 (da) * 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
AU8746582A (en) 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
EP0301083A4 (en) * 1987-02-11 1990-09-26 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
FR2635115B1 (fr) * 1988-08-05 1992-04-03 Rhone Poulenc Sante Procede de preparation de la serum albumine humaine a partir d'une levure
CA2009270A1 (en) * 1989-02-06 1990-08-06 Daniel J. Hicklin Stabilized hepatitis e antigen suitable for immunoassays
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases

Also Published As

Publication number Publication date
AU1146692A (en) 1992-09-10
JP3329848B2 (ja) 2002-09-30
DK0503252T3 (da) 2001-07-02
PT503252E (pt) 2001-09-28
ES2155436T3 (es) 2001-05-16
JPH07203971A (ja) 1995-08-08
DE59209899D1 (de) 2001-05-10
DE4107612A1 (de) 1992-09-10
CA2062410A1 (en) 1992-09-10
EP0503252A2 (de) 1992-09-16
AU664982B2 (en) 1995-12-14
EP0503252B1 (de) 2001-04-04
US6277631B1 (en) 2001-08-21
EP0503252A3 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
NZ236491A (en) Post-transfusional non-a non-b hepatitis viral polypeptides, dna, antigenic polypeptides and antibodies to the polypeptides
PH25249A (en) Method for producing hepatitis b virus proteins in yeast
EP0608261A4 (en) COMPOSITION OF AN IMMUNREACTIVE HEPATITIS C VIRUS POLYPEPTIDE.
EP0109942A3 (en) Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
AU9052091A (en) Vaccines based on hepatitis b surface antigen
GR3017804T3 (en) Hepatitis b vaccine.
WO1993001210A3 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
FI823021A7 (fi) Tuotteet, jotka osoittavat hepatitis B virus e antigeenin antigeenisuuden ja menetelmät näiden antigeenien vavalmistamiseksi.
HUT60772A (en) Process for producing non-a, non-b hepatitis virus genomial cdna and antigen polypeptide
MX9603182A (es) Vacuna de hepatitis b.
WO1994024291A3 (en) Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation
AU1459792A (en) Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
ZA894182B (en) Method for producing nonhyperglycosylated hepatitis b virus proteins
NZ219516A (en) Fusion proteins of hbcag (hepatitis b virus core antigen)
NZ239948A (en) Hiv gp160 modified at positions 502 and 510, vaccines and recombinant methods for producing modified gp160
AU6358190A (en) Polypeptide vaccines against foot-and-mouth disease virus
EP0503252A3 (en) Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines
EP0314240A3 (en) Process for purifying recombinant hepatitis antigens
AP9300556A0 (en) Peptides,analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus
AU7909391A (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
AU3269793A (en) Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it
IE880242L (en) Hepatitis b virus antigens.
PL273721A1 (en) Method of obtaining a polypeptide exhibiting antigenic properties in respect to the pre s1 region of hepatitis virus a areole

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees